Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node‐Positive Breast Cancer: Real World Data
Total pCR is still the best marker for predicting survival benefit in patients receiving neoadjuvant chemotherapy, and total pCR is more likely to be achieved in patients with HR-negative disease and a high Ki-67 proliferation index. T stage and N stage may predict apCR and bpCR, respectively.
Authors
- Binghe Xu (ORCID: https://orcid.org/0000-0003-4195-337X)
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Danyang Ji (ORCID: https://orcid.org/0000-0003-1721-9482)
- Bo Lan (ORCID: https://orcid.org/0000-0002-2962-439X)
- Jiayu Wang (ORCID: https://orcid.org/0000-0003-0558-8643)
- Qiao Li (ORCID: https://orcid.org/0000-0002-4547-1266)
- Qing Li (ORCID: https://orcid.org/0000-0002-9258-508X)
- Shanshan Chen (ORCID: https://orcid.org/0000-0001-9723-2403)
- Pin Zhang (ORCID: https://orcid.org/0000-0002-7141-9541)
- Ying Fan
- Yang Luo (ORCID: https://orcid.org/0000-0001-5387-3954)
- Ruigang Cai
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1111/1759-7714.70035
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00